Keywords: Ab, antibody; CT, computerized tomography; CTLA-4, cytotoxic T-lymphocyte–associated protein 4; PD-1, programmed cell death-1 receptor; drug reaction; irAEs, immune-related adverse events; leukocytoclastic vasculitis; programmed cell death-1 receptor inhibition; small bowel vasculitis.